cytarabine and imatinib mesylate

cytarabine has been researched along with imatinib mesylate in 133 studies

Research

Studies (133)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.75)	18.2507
2000's	96 (72.18)	29.6817
2010's	33 (24.81)	24.3611
2020's	3 (2.26)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Coffey, ET; Courtney, MJ	1
Druker, BJ; Kolibaba, KS; Ohno-Jones, S; Thiesing, JT	1
Fruehauf, S; Topaly, J; Zeller, WJ	1
Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S	1
Brunstein, CG; Mcglave, PB	1
Ohnishi, K	1
Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S	2
Davidson, RJ; Goldman, JM; Gordon, MY; Marley, SB	1
Draznin, J; Parisi, E; Porter, D; Schuster, SJ; Sollecito, TP; Stoopler, E	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Talpaz, M; Thomas, DA	1
Joel, SP; Liu, WM; Stimson, LA	1
Kharbanda, S; Kufe, D; Kumar, S; Mishra, N; Raina, D; Saxena, S	1
Apperley, J; Clark, R; Goldman, J; Green, T; Holyoake, T; O'Brien, S; Shepherd, P	1
Ault, P; Cortes, J; Kaled, ES; Kantarjian, H; Koller, C	1
Bali, P; Bhalla, K; Burnette, PK; Huang, M; Jove, R; Loughran, T; Nimmanapalli, R; O'Bryan, E; Tepperberg, J	1
Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P	1
Berger, U; Engelich, G; Helmann, R	1
Hentrich, M; Ledderose, G; Salat, C; Stoetzer, OJ	1
Hentrich, M; Salat, C; Stoetzer, OJ	1
Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P	1
Breitenbuecher, F; Fischer, T; Gamm, H; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A	1
Baccarani, M; Bolton, AE; Capdeville, R; Cervantes, F; Cornelissen, JJ; Druker, BJ; Fischer, T; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Lechner, K; Nielsen, JL; O'Brien, SG; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Taylor, K; Verhoef, G	1
Baron, F; Beguin, Y; Fillet, G; Hafraoui, K; Humblet-Baron, S	1
Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F	1
Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T	1
Brandwein, J; Gupta, V; Kamel-Reid, S; Lipton, JH; Messner, HA; Minden, MD	1
Breitenbuecher, F; Carius, B; Fischer, T; Gschaidmeier, H; Huber, C; Kasper, S; Kindler, T; Stevens, T	1
Cella, D; Dobrez, DG; Druker, BJ; Glendenning, GA; Guilhot, F; Hahn, EA; Hensley, ML; Hudgens, SA; Larson, RA; O'Brien, SG; Sorensen, MV	1
Deininger, MW; O'Brien, SG	1
Glendenning, GA; Hahn, EA	1
Berthaud, P; Berthou, C; Buzyn, A; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Najman, A; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M	1
Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA	1
Berthaud, P; Berthou, C; Buzyn, A; Cheron, N; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M	1
Andreeff, M; Cortes, J; Faderl, S; Freireich, E; Garcia-Manero, G; Giles, F; Kantarjian, HM; Kornblau, S; Mallard, S; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; White, K	1
Barete, S; Bonté, I; Casassus, P; de Gennes, C; Fain, O; Hermine, O; Lortholary, O; Marrache, F; Mémain, N	1
Agis, H; Geissler, K; Mannhalter, C; Mayerhofer, M; Sagaster, V; Sillaber, C; Sperr, WR; Valent, P	1
Arthur, C; Bradstock, K; Branford, S; Browett, P; Durrant, S; Gathmann, I; Grigg, A; Harper, A; Hughes, TP; Joske, D; Lynch, K; Ma, D; Rudzki, Z; Schwarer, AP; Seymour, JF; Taylor, K	1
Aulitzky, W; Berger, U; Berndt, A; Deininger, MW; Fischer, T; Freund, M; Fruehauf, S; Gattermann, N; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Hossfeld, DK; König, H; Krause, SW; Kreil, S; Lahaye, T; le Coutre, P; Merx, K; Müller, MC; Nerl, C; Neubauer, A; Ottmann, OG; Paschka, P; Sayer, HG; Schneller, F; Waller, C	1
Löwenberg, B	1
Bolton, AE; Branford, S; Gathmann, I; Goldman, JM; Hensley, ML; Hochhaus, A; Hughes, TP; Kaeda, J; Radich, JP; Rudzki, Z; van Hoomissen, IC	1
Berger, U; Engelich, G; Hehlmann, R; Hochhaus, A; Reiter, A	1
Berger, U; Hehlmann, R	1
Giakoumi, X; Mantzouranis, M; Pangalis, GA; Vassilakopoulos, TP; Viniou, NA	1
Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T	1
Ueda, T	1
Ascani, S; Bonomini, S; Caramatti, C; Colla, S; Craviotto, L; Crugnola, M; De Celis, I; Giuliani, N; Hojden, M; Morandi, F; Rizzoli, V; Sabbatini, E; Sammarelli, G	1
Bujassoum, S; Lipton, JH; Rifkind, J	1
Bornhäuser, M; Braess, J; Ehninger, G; Freiberg-Richter, J; Illmer, T; Köhne, Ch; Le Coutre, P; Ottmann, OG; Platzbecker, U; Pursche, J; Schaich, M; Schleyer, E; Thiede, C; von Bonin, M	1
Borthakur, G; Cortes, JE	1
Allen, AS; Anstrom, KJ; Glendenning, GA; Reed, SD; Schulman, KA	1
Anstrom, KJ; Glendenning, GA; Ludmer, JA; Reed, SD; Schulman, KA	1
Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S	1
Aceves Luquero, CI; Alvarez-Vallina, L; Galán Moya, EM; Gayoso Cruz, J; Hernández Losa, J; Melo, JV; Parada Cobo, C; Ramón y Cajal, S; Sánchez-Arévalo Lobo, VJ; Sánchez-Prieto, R; Tipping, AJ; Viniegra, JG	1
Cassileth, PA; Morgensztern, D; Raez, LE; Rosado, MF; Santos, ES	1
Cortes, J; Dewald, GW; Kantarjian, HM; Litzow, ML; Mauro, MJ; Talpaz, M; Tefferi, A	1
Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L	1
Aleskog, A; Barbany, G; Björnberg, A; Hallböök, H; Larsson, R; Lindhagen, E; Sundström, C	1
Raghunadharao, D; Rajappa, S; Rao, IS; Surath, A; Uppin, SG	1
Fay, M; Goldman, J; Murphy, PT; O'Donnell, R; Quinn, J; Swords, R	1
Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B	1
Clapisson, G; Hayette, S; Michallet, M; Nicolini, FE; Philip, I; Prebet, T; Tigaud, I	1
Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M	1
Hong-eng, S; Limsuwan, A; Pakakasama, S; Rochanawutanon, M	1
Druker, BJ; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Krahnke, T; Larson, RA; Massimini, G; O'Brien, S; Roy, L; So, C	1
Heim, D	1
Urabe, A	1
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S	1
Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B	1
Selleslag, D	1
Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F	1
Agis, H; Baccarani, M; Cervantes, F; Cornelissen, JJ; Deininger, MW; Druker, BJ; Fischer, T; Gabrilove, JL; Gathmann, I; Gattermann, N; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Letvak, L; Nielsen, JL; O'Brien, SG; Powell, BL; Radich, JP; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Silver, RT; Simonsson, B; So, C; Stone, RM; Taylor, K; Verhoef, G	1
Aulitzky, W; Cortes, J; Döhner, H; Fischer, T; Heidel, F; Huber, C; Kantarjian, H; Kindler, T; Letvak, L; Rücker, FG	1
Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I	1
Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W	1
Carella, AM	1
Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP	1
Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J	1
Barbu, V; Carbonne, B; Garderet, L; Gorin, NC; Santacruz, R; van den Akker, J	1
Brocca, MC; Coppi, MR; Mele, G; Melpignano, A; Pinna, S; Quarta, G; Romano, A	1
Lenhart, S; Moore, H; Nanda, S	1
Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P	1
Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH	1
Beverloo, HB; Cornelissen, JJ; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Kluin-Nelemans, HC; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, P; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Westveer, PH; Wijermans, PW; Willemze, R; Wittebol, S	1
Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA	1
Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR	1
Cornelissen, JJ; Schnog, JB; Van Hest, RM; Van't Veer, MB	1
Seth, R; Thavaraj, V	1
Bousema, MT; Hayes, DP; Kardaun, SH; Kramer, MH; Timmer-de Mik, L	1
Li, Y; Mi, Y; Qiu, L; Wang, J; Zhao, Y; Zou, D	1
Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR	1
Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S	1
Druker, B; Gathmann, I; Guilhot, F; Larson, RA; O'Brien, SG; So, C; Waltzman, R	1
Berendse, HW; Janssen, JJ; Merle, PA; Ossenkoppele, GJ; Schuurhuis, GJ	1
Hackanson, B; Lübbert, M; Rückert, A	1
Ozawa, K	1
Arnold, R; Beelen, DW; Bunjes, D; Dengler, R; Falge, C; Gratwohl, A; Haferlach, C; Hasford, J; Hehlmann, R; Ho, AD; Hochhaus, A; Holler, E; Kanz, L; Kolb, HJ; Lauseker, M; Leitner, A; Müller, MC; Pfirrmann, M; Pletsch, N; Saussele, S; Schlegelberger, B; Schlimok, G; Schnittger, S; Schwerdtfeger, R; Zander, AR	1
Beverloo, HB; Cornelissen, JJ; Daenen, SM; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, PJ; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Wijermans, PW; Willemze, R; Wittebol, S	1
Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M	1
Ohno, R	1
Advani, AS; Bates, J; Copelan, EA; Cotta, CV; Egorin, MJ; Howard, M; Hsi, E; Jin, T; Kalaycio, M; Lim, K; Maciejewski, J; Noon, E; Price, C; Rush, ML; Salvado, A; Saunthararajah, Y; Sekeres, MA; Sobecks, R; Tiu, R; Tripp, B	1
Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR	1
Allard, C; Berger, M; Berthou, C; Coiteux, V; Corm, S; Delmer, A; Eclache, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Jourdan, E; Legros, L; Mahon, FX; Maloisel, F; Nicolini, FE; Preudhomme, C; Rea, D; Rigal-Huguet, F; Roche-Lestienne, C; Rousselot, P; Vekhoff, A	1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A	1
Barbagallo, I; Chiarenza, A; Conticello, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Romano, A; Stagno, F; Tibullo, D	1
Fujisaki, T; Moriyama, Y; Muta, T; Sawada, Y; Seike, Y; Tokuyama, T; Ueda, Y	1
Broome, HE; Curtin, PT; Dell'Aquila, ML; Rashidi, HH; Thorson, JA; Wang, HY	1
Chen, X; Yang, W; Zhu, X	1
Cho, JH; Hur, M; Kim, WS; Ko, YS; Lee, MH; Moon, HW; Yun, YM	1
Baerlocher, GM; Branford, S; Dengler, J; Einsele, H; Erben, P; Fabarius, A; Falge, C; Göhring, G; Haferlach, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Hughes, TP; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saußele, S; Schnittger, S; Schubert, J; Spiekermann, K; Stegelmann, F; Waller, CF	1
Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C	1
Caruso, M; de Campos-Lima, PO; Ghani, K; Naud, JS	1
Abella, E; Amigo, ML; Barrios, M; Bravo, P; Brunet, S; García, O; González-Campos, J; Hernández-Rivas, JM; Montesinos, P; Ribera, JM	1
Chen, SN; Dai, HP; Gong, YL; Pan, JL; Wu, DP; Wu, LL; Wu, YF; Xue, YQ; Zhang, J	1
Ammerlaan, RA; Chu, IW; Cornelissen, JJ; Deenik, W; Falkenburg, JH; Janssen, JJ; Kersten, MJ; Ossenkoppele, GJ; Schattenberg, A; Schipperus, M; Sinnige, HA; Smit, WM; Sonneveld, P; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE	1
Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S	1
Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D	1
Dengler, J; Fabarius, A; Falge, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Hochhaus, A; Hossfeld, DK; Kalmanti, L; Kanz, L; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saussele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF	1
Baerlocher, GM; Dengler, J; Ehninger, G; Einsele, H; Fabarius, A; Falge, C; Haferlach, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Pletsch, N; Proetel, U; Saußele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF	1
Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J	1
Biswas, J; Biswas, R; Mukherjee, A; Mukherjee, S; Roy, M; Sarkar, R	1
Koh, K	1
Bartholomäus, A; Bentz, M; Berdel, WE; Burchert, A; de Wit, M; Eckart, MJ; Fabarius, A; Gassmann, W; Hahn, M; Hanfstein, B; Hasford, J; Hebart, HF; Hehlmann, R; Heim, D; Heymanns, J; Hochhaus, A; Hofmann, WK; Kalmanti, L; Kraemer, D; Krause, SW; Krauss, MP; Lauseker, M; Leibundgut, EO; Müller, MC; Pezzutto, A; Pfirrmann, M; Proetel, U; Saussele, S; Schmidt-Wolf, I; Schmitz, N; Staib, P; Wernli, M; Zettl, F	1
Bae, SH; Chi, HS; Eom, HS; Hyun, MS; Jang, DY; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, HJ; Kim, I; Kim, MK; Lee, GW; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, S; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yun, SC	1
Hayakawa, F; Kato, H; Miyata, Y; Mizuno, H; Nakayama, T; Naoe, T; Nishiwaki, S; Saito, S; Sugimoto, K; Suzuki, R; Takami, A; Takeshita, K; Ueda, R	1
Baccarani, M; Branford, S; Cervantes, F; Deininger, MW; Druker, BJ; Fujihara, S; Guilhot, F; Hochhaus, A; Hughes, TP; Kantarjian, H; Larson, RA; Menssen, HD; O'Brien, SG; Ortmann, CE; Radich, JP	1
Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K	1
Dağlı, M; Keles Oğlu, KS; Koplay, M; Paksoy, Y; Sivri, M	1
Guo, X; Zhang, X	1
Iriyama, N; Kawaguchi, T; Kirito, K; Kizaki, M; Shimoda, K; Takahashi, N	1
Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W	1
Alexis, M; Arkam, Y; Berger, M; Berthou, C; Bulabois, CE; Caillot, D; Cambier, N; Cayuela, JM; Chapiro, J; Charbonnier, A; Chomel, JC; Coiteux, V; Cony-Makhoul, P; Deconinck, E; Delmer, A; Delord, M; Dorvaux, V; Dubruille, V; Escoffre Barbe, M; Etienne, G; Fouillard, L; Gardembas, M; Ghomari, K; Glaisner, S; Guerci-Bresler, AP; Guilhot, F; Guilhot, J; Gyan, E; Johnson-Ansah, H; Joly, B; Jourdan, E; Kiladjian, JJ; Lebon, D; Legros, L; Lenain, P; Lhermitte, L; Mahon, FX; Maisonneuve, H; Maloisel, F; Mercier, M; Miclea, JM; Muller, M; Nicolini, FE; Penot, A; Plantier, I; Pollet, B; Preudhomme, C; Rea, D; Rigal-Huguet, F; Rousselot, P; Roy, L; Santagostino, A; Vaida, I; Vekhoff, A; Zerazhi, H	1

Reviews

24 review(s) available for cytarabine and imatinib mesylate

Article	Year
The biology and treatment of chronic myelogenous leukemia. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Survival Analysis	2001
[Chronic myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Survival Rate	2001
Acute myelogenous leukemia: advances and limitations of treatment. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 93, Issue:3 Topics: Adult; Aminoglycosides; Anthracyclines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Case-Control Studies; Cytarabine; Fatal Outcome; Gemtuzumab; Gingiva; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Immunotoxins; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Piperazines; Pyrimidines; Remission Induction; Sialic Acid Binding Ig-like Lectin 3	2002
[Chronic myeloid leukemia--treatment]. Deutsche medizinische Wochenschrift (1946), 2002, Dec-06, Volume: 127, Issue:49 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Risk Factors; Stem Cell Transplantation	2002
[How I treat...chronic myeloid leukemia]. Revue medicale de Liege, 2003, Volume: 58, Issue:1 Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2003
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Protocols; Clinical Trials as Topic; Cytarabine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines	2003
[Treatment of systemic mastocytosis]. La Revue de medecine interne, 2003, Volume: 24, Issue:9 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Cladribine; Cytarabine; Diphosphonates; Enzyme Inhibitors; Histamine H1 Antagonists; Humans; Imatinib Mesylate; Interferon-alpha; Mastocytosis, Systemic; Photochemotherapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines	2003
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Clinical Trials as Topic; Cytarabine; Diagnosis, Differential; Drug Resistance; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Risk Factors; Sirolimus; Stem Cell Transplantation; Time Factors	2003
[Recent progress in diagnosis of and therapy for patients with leukemia]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Mar-10, Volume: 93, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Targeting; Genes, Wilms Tumor; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Pharmacogenetics; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Therapeutic Equivalency; Tretinoin	2004
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. European journal of haematology, 2004, Volume: 72, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Burkitt Lymphoma; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Remission Induction	2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. Annals of hematology, 2004, Volume: 83 Suppl 1 Topics: Antigens, CD; Antigens, CD34; Benzamides; Bone Marrow Cells; Cell Line, Tumor; Cytarabine; Gene Deletion; Genes, abl; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines	2004
Imatinib mesylate in the treatment of chronic myelogenous leukemia. International journal of hematology, 2004, Volume: 79, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation	2004
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. American journal of hematology, 2004, Volume: 77, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2004
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clinic proceedings, 2005, Volume: 80, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Treatment Outcome	2005
[Tyrosine kinase inhibitors for the treatment of CML]. Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase II as Topic; Cytarabine; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors	2006
[Chronic myelogenous leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Therapy, Combination; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2006
Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. PharmacoEconomics, 2008, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Survival Analysis	2008
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic	2009
[History, current status, and future prospects in clinical study of myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Design; Drug Therapy, Combination; Gene Targeting; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Precision Medicine; Pyrimidines; Remission Induction; Risk; Tretinoin	2009
Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Current hematologic malignancy reports, 2006, Volume: 1, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Multicenter Studies as Topic; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate; Vincristine	2006
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Current medicinal chemistry, 2011, Volume: 18, Issue:5 Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1	2011
Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature. Human pathology, 2012, Volume: 43, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Back; Benzamides; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Endometrial Neoplasms; Female; Gene Rearrangement; Genes, abl; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Leukemic Infiltration; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Soft Tissue Neoplasms; Submandibular Gland Neoplasms; Translocation, Genetic	2012
[Current treatment of pediatric acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Topic; Cytarabine; Dexamethasone; Drug Discovery; Humans; Imatinib Mesylate; Induction Chemotherapy; Mercaptopurine; Methotrexate; Molecular Targeted Therapy; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines	2014
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). International journal of hematology, 2020, Volume: 112, Issue:3 Topics: Cytarabine; Dasatinib; Drug Monitoring; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines	2020

Trials

36 trial(s) available for cytarabine and imatinib mesylate

Article	Year
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia, 2001, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2001
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytarabine; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome	2002
[Imatinib combination therapies--the new CML Study 4]. Deutsche medizinische Wochenschrift (1946), 2002, Oct-18, Volume: 127, Issue:42 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome	2002
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England journal of medicine, 2003, Mar-13, Volume: 348, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Survival Rate	2003
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-01, Volume: 21, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Prospective Studies; Pyrimidines; Quality of Life	2003
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome	2003
Quality of life on imatinib. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome	2003
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood, 2003, Dec-15, Volume: 102, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Safety; Thrombocytopenia	2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer, 2003, Sep-01, Volume: 98, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Drug Administration Schedule; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2003
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003, Volume: 17, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bone Marrow; Cross-Over Studies; Cytarabine; Cytogenetics; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases; Piperazines; Prognosis; Protein Structure, Tertiary; Pyrimidines; Treatment Outcome	2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 2003, Volume: 17, Issue:12 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Cytogenetics; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Risk Factors; RNA, Messenger; Treatment Outcome	2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England journal of medicine, 2003, Oct-09, Volume: 349, Issue:15 Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2003
Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Annals of hematology, 2004, Volume: 83, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Prospective Studies; Pyrimidines; Survival Rate	2004
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study]. Der Internist, 2004, Volume: 45, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome	2004
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, Feb-15, Volume: 109, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Transplantation, Homologous	2007
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England journal of medicine, 2006, Dec-07, Volume: 355, Issue:23 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Survival Rate; Treatment Outcome	2006
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer, 2007, Mar-01, Volume: 109, Issue:5 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Stem Cell Factor; Survival Rate; Treatment Outcome	2007
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome	2007
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 2007, Apr-15, Volume: 109, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2007
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood, 2008, Mar-01, Volume: 111, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Communicable Diseases; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Tests; Humans; Imatinib Mesylate; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mortality; Piperazines; Pyrimidines	2008
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leukemia research, 2008, Volume: 32, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors	2008
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica, 2009, Volume: 94, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Diarrhea; Drug Administration Schedule; Edema; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Nausea; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome	2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, Mar-11, Volume: 115, Issue:10 Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous	2010
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica, 2010, Volume: 95, Issue:6 Topics: Adult; Aged; Benzamides; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult	2010
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leukemia research, 2010, Volume: 34, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; STAT5 Transcription Factor	2010
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leukemia research, 2011, Volume: 35, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Exanthema; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult	2011
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26 Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Polyethylene Glycols; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombinant Proteins; Remission Induction; RNA, Neoplasm; Stem Cells; Survival Analysis; Thrombocytopenia; Transcription, Genetic; Treatment Outcome	2010
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 2012, Volume: 26, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Young Adult	2012
Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. British journal of haematology, 2012, Volume: 159, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Imatinib Mesylate; Male; Mercaptopurine; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Vincristine; Young Adult	2012
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Annals of hematology, 2013, Volume: 92, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Treatment Outcome; Young Adult	2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult	2014
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood, 2015, Jul-02, Volume: 126, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Comorbidity; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult	2015
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Vincristine	2015
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England journal of medicine, 2017, 03-09, Volume: 376, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Intention to Treat Analysis; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Young Adult	2017
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:12 Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome	2017
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 2021, Volume: 35, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate; Young Adult	2021

Other Studies

73 other study(ies) available for cytarabine and imatinib mesylate

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
The mechanism of Ara-C-induced apoptosis of differentiating cerebellar granule neurons. The European journal of neuroscience, 1999, Volume: 11, Issue:3 Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzamides; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cell Differentiation; Cell Survival; Cerebellum; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Cytarabine; Enzyme Inhibitors; Flavonoids; Imatinib Mesylate; Imidazoles; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinases; Neurons; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Purines; Pyridines; Pyrimidines; Rats; Roscovitine; Signal Transduction; Stress, Physiological; Wortmannin	1999
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 2000, Nov-01, Volume: 96, Issue:9 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Cell Survival; Cytarabine; Daunorubicin; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-3; Leukemia, Megakaryoblastic, Acute; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Stem Cell Factor; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine	2001
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Benzamides; Cell Division; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interleukin-3; Kinetics; Leukemia, Myeloid, Acute; Leukocyte Count; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Recurrence; Signal Transduction; Stem Cell Factor	2001
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. British journal of haematology, 2002, Volume: 116, Issue:1 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzamides; Cell Division; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cells; Tretinoin; Tyrphostins	2002
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. British journal of cancer, 2002, May-06, Volume: 86, Issue:9 Topics: Antineoplastic Agents; Benzamides; Cell Death; Cytarabine; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured	2002
Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Molecular pharmacology, 2002, Volume: 61, Issue:6 Topics: Antimetabolites, Antineoplastic; Apoptosis; Benzamides; Caspase 3; Caspases; Cytarabine; Drug Delivery Systems; Drug Interactions; Enzyme Activation; Humans; Imatinib Mesylate; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Tumor Cells, Cultured	2002
Not so NICE for CML. Lancet (London, England), 2002, Jun-08, Volume: 359, Issue:9322 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Approval; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome	2002
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia research, 2002, Volume: 26, Issue:9 Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modality Therapy; Consciousness Disorders; Cytarabine; Drug Resistance, Multiple; Enzyme Inhibitors; Fatal Outcome; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Indomethacin; Infarction; Male; Middle Aged; Mitral Valve Stenosis; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Splenectomy	2002
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer, 2002, May-15, Volume: 94, Issue:10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; Homoharringtonine; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer research, 2002, Oct-15, Volume: 62, Issue:20 Topics: Benzamides; Benzoquinones; Blast Crisis; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidines; Rifabutin; src-Family Kinases; STAT5 Transcription Factor; Trans-Activators	2002
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction	2003
[Chronic myeloid leukemia--case report]. Deutsche medizinische Wochenschrift (1946), 2002, Dec-06, Volume: 127, Issue:49 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Cytarabine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Piperazines; Prognosis; Pyrimidines; Remission Induction	2002
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. Bone marrow transplantation, 2002, Volume: 30, Issue:12 Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine	2002
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood, 2003, Apr-15, Volume: 101, Issue:8 Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Exons; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence; Remission Induction; Salvage Therapy	2003
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Molecular cancer therapeutics, 2003, Volume: 2, Issue:3 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured	2003
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias. Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hepatitis B; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lamivudine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Salvage Therapy; Vincristine	2003
In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia, 2003, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Caspases; Cell Division; Cytarabine; DNA; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Phosphorylation; Piperazines; Poly(ADP-ribose) Polymerases; Precipitin Tests; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Tyrosine; U937 Cells	2003
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4 Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate	2003
Minimal residual disease in chronic myeloid leukemia. The New England journal of medicine, 2003, Oct-09, Volume: 349, Issue:15 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2003
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. European journal of haematology, 2004, Volume: 72, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vidarabine	2004
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. International journal of hematology, 2004, Volume: 79, Issue:1 Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorubicin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxyurea; Imatinib Mesylate; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Pyrimidines; Vincristine; Zoledronic Acid	2004
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leukemia & lymphoma, 2004, Volume: 45, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction	2004
Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, Dec-01, Volume: 101, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Treatment Outcome	2004
Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, Dec-01, Volume: 101, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cost-Benefit Analysis; Cytarabine; Health Care Costs; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Retrospective Studies; Survival Analysis	2004
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. The Biochemical journal, 2005, Apr-01, Volume: 387, Issue:Pt 1 Topics: Benzamides; Cell Line; Cell Line, Tumor; Cytarabine; DNA-Binding Proteins; Enzyme Activation; Fusion Proteins, bcr-abl; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Kidney; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Tumor Protein p73; Tumor Suppressor Proteins; U937 Cells	2005
Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2005
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 2005, Volume: 19, Issue:7 Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin	2005
In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia. Anti-cancer drugs, 2005, Volume: 16, Issue:6 Topics: Adult; Antineoplastic Agents; Asparaginase; Benzamides; Cell Survival; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Fluorometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mercaptopurine; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Pyrimidines; Tumor Cells, Cultured; Vincristine	2005
Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematological oncology, 2004, Volume: 22, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meninges; Methotrexate; Neoplasm Invasiveness; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2004
CML clonal evolution with resistance to single agent imatinib therapy. Clinical and laboratory haematology, 2005, Volume: 27, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Trisomy	2005
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica, 2005, Volume: 90 Suppl Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine	2005
Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib. Haematologica, 2005, Volume: 90 Suppl Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Interferons; Lenograstim; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Autologous	2005
Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2005, Volume: 3, Issue:6 Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous	2005
Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology, 2006, Volume: 105, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Hyperplasia; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vasodilator Agents	2006
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 2006, Sep-01, Volume: 108, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Survival Analysis; Treatment Failure; Treatment Outcome	2006
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Investigational new drugs, 2007, Volume: 25, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Cytarabine; Depsipeptides; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; Irinotecan; K562 Cells; Leukemia; Lymphoma; Mercaptopurine; Piperazines; Pyrimidines; Time Factors	2007
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine	2006
A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta bio-medica : Atenei Parmensis, 2006, Volume: 77 Suppl 2 Topics: Abscess; Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytarabine; Foot Dermatoses; Fusarium; Humans; Imatinib Mesylate; Immunocompromised Host; Liposomes; Male; Middle Aged; Muscular Diseases; Onychomycosis; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction; Reoperation; Rituximab; Teniposide; Triazoles; Voriconazole	2006
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. Journal of neuro-oncology, 2007, Volume: 84, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome	2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia & lymphoma, 2007, Volume: 48, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome	2007
Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia. Expert review of anticancer therapy, 2007, Volume: 7, Issue:3 Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Binding Sites; Cross-Over Studies; Cytarabine; Disease-Free Survival; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Europe; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm Proteins; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; src Homology Domains; Transplantation, Homologous; Treatment Outcome	2007
Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica, 2007, Volume: 92, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Feeding; Cytarabine; Embryonic Development; Female; Humans; Imatinib Mesylate; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Recurrence; Remission Induction	2007
What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL? Leukemia research, 2007, Volume: 31, Issue:10 Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiotherapy; Salvage Therapy	2007
Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Mathematical biosciences, 2007, Volume: 210, Issue:1 Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mathematics; Models, Biological; Piperazines; Pyrimidines; T-Lymphocytes	2007
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. European journal of clinical investigation, 2007, Volume: 37, Issue:10 Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2007
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2007
Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib. American journal of hematology, 2008, Volume: 83, Issue:9 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Drug Interactions; Edema; Etoposide; Female; Humans; Imatinib Mesylate; Leucovorin; Methotrexate; Middle Aged; Piperazines; Pleural Effusion, Malignant; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Sodium Potassium Chloride Symporter Inhibitors; Translocation, Genetic	2008
Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World journal of pediatrics : WJP, 2008, Volume: 4, Issue:2 Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood Cell Count; Central Nervous System Neoplasms; Chemoprevention; Child; Clinical Protocols; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Methotrexate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction	2008
Imatinib-induced pseudoporphyria. Clinical and experimental dermatology, 2009, Volume: 34, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Cytarabine; Drug Eruptions; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Porphyrias; Pyrimidines	2009
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Salvage Therapy; Vincristine; Vindesine; Young Adult	2009
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leukemia & lymphoma, 2009, Volume: 50, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome	2009
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 2009, Sep-10, Volume: 114, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine	2009
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American journal of hematology, 2009, Volume: 84, Issue:10 Topics: Antineoplastic Agents; Aphasia; Ataxia; Benzamides; Blast Crisis; Confusion; Cytarabine; Diagnosis, Differential; Hearing Loss; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2009
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. Acta haematologica, 2010, Volume: 123, Issue:4 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles	2010
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European journal of haematology, 2011, Volume: 86, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cytarabine; DNA Damage; Drug Synergism; Gene Expression; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Piperazines; Pyrimidines; Tumor Stem Cell Assay	2011
[Chronic myeloid leukemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:12 Topics: Acute Disease; Antineoplastic Agents; Benzamides; Cerebellum; Cerebral Hemorrhage; Combined Modality Therapy; Critical Care; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocephalus; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Mannitol; Middle Aged; Piperazines; Pyrimidines; Respiration, Artificial	2010
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. Human pathology, 2011, Volume: 42, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Cytarabine; Female; Flow Cytometry; Humans; Idarubicin; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Karyotype; Karyotyping; Leukemia, Biphenotypic, Acute; Middle Aged; Phenotype; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic	2011
Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia. Pediatrics international : official journal of the Japan Pediatric Society, 2011, Volume: 53, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cytarabine; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Piperazines; Pyrimidines	2011
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia. Gene, 2012, Jun-15, Volume: 501, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine	2012
Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy. Leukemia research, 2012, Volume: 36, Issue:10 Topics: Benzamides; Cytarabine; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thymidine; Tumor Cells, Cultured	2012
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16). International journal of hematology, 2012, Volume: 96, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 16; Combined Modality Therapy; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Male; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction	2012
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood, 2013, Aug-15, Volume: 122, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult	2013
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer, 2014, Feb-01, Volume: 120, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine	2014
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; RNA, Messenger; RNA, Neoplasm; Splenomegaly; Treatment Outcome; Young Adult	2014
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:7 Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2014, Volume: 33, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Cycle Checkpoints; Curcumin; Cytarabine; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Heat Shock Transcription Factors; Heat-Shock Proteins; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Oxidative Stress; Piperazines; Pyrimidines; Transcription Factors	2014
Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions. Scientific reports, 2016, 08-02, Volume: 6 Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cytarabine; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; Imatinib Mesylate; Leukemia; Mice; Neoplasm Transplantation; Osteoblasts; Tumor Microenvironment	2016
An atypical isolated CNS blast crisis in chronic myeloid leukaemia. British journal of hospital medicine (London, England : 2005), 2018, Aug-02, Volume: 79, Issue:8 Topics: Aged; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System Diseases; Cytarabine; Glucocorticoids; Humans; Image Enhancement; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Methotrexate; Neuroimaging; Spinal Cord; Treatment Outcome	2018
Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Proteins; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction	2019
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report. Current medical research and opinion, 2020, Volume: 36, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous	2020